Early Management of NSTE-ACS: From the ED to the Cath Lab

21

description

Early Management of NSTE-ACS: From the ED to the Cath Lab. Main Limitations of UFH. Fondaparinux*. Bivalirudin. Otamixaban. Early Management of NSTE-ACS: From the ED to the Cath Lab. Evaluation of Chest Pain. ACCF/AHA Recommendations for Initial Management of UA/NSTEMI. - PowerPoint PPT Presentation

Transcript of Early Management of NSTE-ACS: From the ED to the Cath Lab

Page 1: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 2: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 3: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 4: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 5: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 6: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 7: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 8: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 9: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 10: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 11: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 12: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 13: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 14: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 15: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 16: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 17: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 18: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 19: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 20: Early Management of NSTE-ACS: From the ED to the Cath Lab
Page 21: Early Management of NSTE-ACS: From the ED to the Cath Lab

The ACUITY Trial randomized 13,819 patients with moderate and high-risk NSTE-ACS.

The ACUITY Trial randomized 13,819 patients with moderate and high-risk NSTE-ACS.

Anticoagulation Therapy in Percutaneous Coronary Interventionsstatic.livemedia.gr/kebe/documents/al17324_us63... · 2015. 9. 11. · Enoxaparin NSTE-ACS No differences in 30-day death/MI*.

Anticoagulation Therapy in Percutaneous Coronary Interventionsstatic.livemedia.gr/kebe/documents/al17324_us63... · 2015. 9. 11. · Enoxaparin NSTE-ACS No differences in 30-day death/MI*.

Final Copy NSTE-ACS for Presentation

Final Copy NSTE-ACS for Presentation

2015 ESC Guidelines for the Management of NSTE-ACS

2015 ESC Guidelines for the Management of NSTE-ACS

NSTE ACS - cdn.ymaws.com€¦ · Risk Stratified by Timing Ischemic Guided (new term) Immediate Invasive < 2 hours Early Invasive < 24 hours Delayed Invasive 25‐72 hours 17 Formerly

NSTE ACS - cdn.ymaws.com€¦ · Risk Stratified by Timing Ischemic Guided (new term) Immediate Invasive < 2 hours Early Invasive < 24 hours Delayed Invasive 25‐72 hours 17 Formerly

2014 AHA/ACC Guideline for the Management of Patients …circ.ahajournals.org/content/circulationaha/early/2014/09/22/CIR... · Amsterdam EA, et al. 2014 AHA/ACC NSTE-ACS Executive

2014 AHA/ACC Guideline for the Management of Patients …circ.ahajournals.org/content/circulationaha/early/2014/09/22/CIR... · Amsterdam EA, et al. 2014 AHA/ACC NSTE-ACS Executive

ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y

ESC Guidelines: oral antiplatelet therapy before and in ... · 9 Recommendations for platelet inhibition in NSTE-ACS 2015 Recommendations Class Level Oral antiplatelet therapy A P2Y

Risk stratification and medical management of NSTE-ACS (UA/NSTEMI ) Dr Sajeer K T.

Risk stratification and medical management of NSTE-ACS (UA/NSTEMI ) Dr Sajeer K T.

Anticoagulation 2013 for NSTEMI and STEMI · zBivalirudin for STEMI, Fondaparinux for NSTE ACS, Coronary stents for ACS ... ≥12 h Sx non ST ↑ACS, mod–high risk ...

Anticoagulation 2013 for NSTEMI and STEMI · zBivalirudin for STEMI, Fondaparinux for NSTE ACS, Coronary stents for ACS ... ≥12 h Sx non ST ↑ACS, mod–high risk ...

BO- Card Cath Lab: ACS

BO- Card Cath Lab: ACS

Perspectives on the Use of Fondaparinux in ACS ... · 1 Perspectives on the Use of Fondaparinux in ACS: transitioning to the Cath Lab Ron Waksman, MD Professor of Medicine (Cardiology)

Perspectives on the Use of Fondaparinux in ACS ... · 1 Perspectives on the Use of Fondaparinux in ACS: transitioning to the Cath Lab Ron Waksman, MD Professor of Medicine (Cardiology)

guidelines ACS NSTE Slides-2011

guidelines ACS NSTE Slides-2011

Chest Pain & Acute Coronary Syndromes (ACS) Clinical Pathway · Chest Pain & Acute Coronary Syndromes (ACS) Discharge Checklist STEMI and High -Risk NSTE-ACS Aspirin Yes No, bleeding

Chest Pain & Acute Coronary Syndromes (ACS) Clinical Pathway · Chest Pain & Acute Coronary Syndromes (ACS) Discharge Checklist STEMI and High -Risk NSTE-ACS Aspirin Yes No, bleeding

2014 Nste Acs Slide Set

2014 Nste Acs Slide Set

Quale, Quando e per Quanto DAPT in NSTE-ACS? - Full Daydocumenti.fullday.com/public/SIMEULAZIO15/slides/DELUCA_SIMEU LAZIO... · VII CONGRESSO REGIONALE SIMEU LAZIO OVERVIEW IN EMERGENCY

Quale, Quando e per Quanto DAPT in NSTE-ACS? - Full Daydocumenti.fullday.com/public/SIMEULAZIO15/slides/DELUCA_SIMEU LAZIO... · VII CONGRESSO REGIONALE SIMEU LAZIO OVERVIEW IN EMERGENCY

Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS ...

Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS ...

Impact of Sex on Comparative Outcomes of Radial Versus ... · presenting with non–ST-segment elevation ACS (NSTE-ACS) were eligible if they had a history consistent with new or

Impact of Sex on Comparative Outcomes of Radial Versus ... · presenting with non–ST-segment elevation ACS (NSTE-ACS) were eligible if they had a history consistent with new or

CRUSADE: Contemporary Evaluation and Management of · PDF fileCRUSADE: Contemporary Evaluation and Management of 200,000 High-Risk NSTE-ACS Patients Page 2 AUGUST 2007 volUme 4 EmErgEncy

CRUSADE: Contemporary Evaluation and Management of · PDF fileCRUSADE: Contemporary Evaluation and Management of 200,000 High-Risk NSTE-ACS Patients Page 2 AUGUST 2007 volUme 4 EmErgEncy

Management of Acute Coronary Syndromes...Management of Non-ST Elevation Acute Coronary Syndromes (NSTE-ACS) April, 2017 Mark Schmidhofer p≤0.05 usually = NS • Nothing magic about

Management of Acute Coronary Syndromes...Management of Non-ST Elevation Acute Coronary Syndromes (NSTE-ACS) April, 2017 Mark Schmidhofer p≤0.05 usually = NS • Nothing magic about

Guidelines on ACS-NSTE (TF21) - Task Force Members and ... · Agewall Stefan Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator,

Guidelines on ACS-NSTE (TF21) - Task Force Members and ... · Agewall Stefan Yes A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator,